D-0185-2021 Class II Terminated
FDA drug recall D-0185-2021 was initiated by Ascend Laboratories LLC on Nov 23, 2020 and is designated Class II. Reason for recall: Failed Impurity/Degradation Specifications: Unidentified impurities not complying with specifications were observed in various lots of Cephalexin FOS USP 125 mg/5 mL. The recall status is terminated (terminated Jun 1, 2023). Affected quantity: 20,232 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 13, 2021
- Initiation Date
- Nov 23, 2020
- Termination Date
- Jun 1, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 20,232 bottles
Product description
Cephalexin for Oral Suspension, USP, 125 mg per 5 mL, packaged as a) 100 ml (when mixed) bottle, NDC 67877-544-88; b) 200 ml (when mixed) bottle NDC 67877-544-68, Rx Only, Manufactured by: Alkem Laboratories, Ltd, Mumbai -400 013 INDIA. Distributed by: Ascend Lab,oratories, LLC Parsippany, NJ 07054
Reason for recall
Failed Impurity/Degradation Specifications: Unidentified impurities not complying with specifications were observed in various lots of Cephalexin FOS USP 125 mg/5 mL.
Distribution pattern
Distributed Nationwide in the USA
Code information
Lot#: a) 19144340, 19144341, Exp AUG 2021; b) 20142226, 20142227, Exp MAY 2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0185-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026